{
  "docId": "019de517-1302-72c9-b1b1-402f68725e8a",
  "docSlug": "8240d0b9060d59c07a4e5f5063c97322",
  "documentTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 11,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/10",
  "deckHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a",
  "deckJsonHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json",
  "deckAnchorHref": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.401,
        "x": 0.539,
        "y": 0.436
      },
      "kind": "callout",
      "text": "Expected cash runway remains into Q4 2024, excluding potential contribution from commercial product revenue if a mAb candidate is authorized or approved",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22ce9bfd-6e90-44aa-849f-782a62352a42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.119,
        "w": 0.379,
        "x": 0.101,
        "y": 0.46
      },
      "kind": "callout",
      "text": "Cash, cash equivalents and marketable securities were $264.9 million as of September 30, 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5476a416-bf91-4447-9889-b623fc73e329",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.139,
        "x": 0.044,
        "y": 0.923
      },
      "kind": "source-note",
      "text": "mAb: monoclonal antibody",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a253c25-1681-4247-84a1-9338388de60c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.039,
        "w": 0.499,
        "x": 0.042,
        "y": 0.104
      },
      "kind": "title",
      "text": "KEY Q3 2023 FINANCIALS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab8c9df5-bffc-46c6-948b-e25b1b060622",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "feb56317-a2e6-4f8a-8b39-db8ce0bbaf5d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The commercialization preparations and financial overview outline the next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}